Published by FACT MR
Posted on September 27, 2021
4 min readLast updated: February 2, 2026
Peptide based cancer therapeutics are projected to grow significantly, with bortezomib drugs leading the market, expected to reach $11,100 Mn by 2022.
Popularity of peptide based cancer therapeutics is on the rise, owing to the positive outlook on their efficiency in treating cancer. According to the latest report published by Fact.MR, the global market for peptide based cancer therapeutics is set to reflect an above average CAGR during 2017 to 2022, to reach a valuation in excess of US$ 11,100 Mn. Incessant development in drug modification, stability, delivery and preclinical achievements is reflecting positively on the future prospects of the global peptide based cancer therapeutics market. Of late, an array of new peptides with encouraging preclinical results are undergoing clinical trials for treating cancer. At the same time, these new peptide are also finding application in various other therapeutic areas. Also, increasing occurrence of cancer is anticipated to be instrumental in boosting the demand for peptide based cancer therapeutics in the near future.
To remain ‘ahead’ of your competitors, request a sample https://www.factmr.com/connectus/sample?flag=S&rep_id=179
As per WHO, over 8 million deaths were recorder globally due to cancer in 2015. Cancer remains one of the foremost causes of death around the world. Factors mentioned above are projected to make a significant influence on the global market for peptide based cancer therapeutics over the forecast period. Moreover, low potency of conventional cancer therapeutics and the adverse side-effects from these therapeutics is prompting physicians to utilise other options. This, in turn, is facilitating the adoption of new-age peptide based therapeutic drugs.
Speak to Research Analyst https://www.factmr.com/connectus/sample?flag=AE&rep_id=179
| Drug |
|
| Distribution Channel |
|
Full Access of this Report Is Available at https://www.factmr.com/checkout/179
Majority of these market players are actively focusing on further product development as well as channelizing their investments in R&D activities.
For More Trending Insights http://www.globenewswire.com/en/news-release/2018/08/21/1554713/0/en/7-Key-Insights-on-Boxing-Gloves-Market-From-Fact-MR-s-Report-through-2022.html
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com
The post Demand for Bortezomib Drugs for Peptide Based Cancer Therapeutics Commands for Nearly 40% Market Share: Fact.MR appeared first on The Cloud Tribune.
The article discusses the market growth of peptide based cancer therapeutics, focusing on bortezomib drugs.
The market is projected to exceed $11,100 million by 2022.
North America is expected to remain the most attractive market.
Explore more articles in the Research Reports category
